Clinical Trials in Germany

• A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants with Cirrhosis-ZEAL-UNLOCK Ended
  2023-506893-11-00 Phase II Cirrhosis of the liver is a condition in which the liver is … Astrazeneca AB
• Open-label single-arm, multicenter clinical trial to evaluate patient acceptability of a new CREON formulation of Pancreas Powder gastro-res… Ended
  2023-503256-27-00 Phase I (Other) patients with cystic fibrosis suffering from pancreatic exoc… MEDA Pharma GmbH & Co. KG
• A phase Ib/II single-arm, multicenter study of sacituzumab-govitecan, a TROP-2 targeting antibody linked with SN38, for patients with metast… Ended
  2023-505257-40-00 Phase I/II metastatic esophagogastric adenocarcinoma (Stage IV) Institut fuer Klinische Krebsforschung IKF GmbH
• MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended
  2023-506425-12-00 Phase III Uncontrolled and Resistant Hypertension Mineralys Therapeutics Inc.
• Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis Ended
  2023-510127-30-00 Phase I Relapsing Remitting Multiple Sclerosis (RRMS) Cellerys AG
• Proof-of-concept study evaluating subcutaneous amlitelimab in adult participants with moderate to severe hidradenitis suppurativa. Ended
  2023-505803-22-00 Phase II Hidradenitis Sanofi-Aventis Research & Development
• A study in people with overweight or obesity to test how BI 1820237, BI 456906, or a combination of both affects brain activity Ended
  2023-506233-30-01 Phase I (Other) Obesity Boehringer Ingelheim International GmbH
• Multi-center study of a fentanyl nasal spray compared with placebo nasal spray for postoperative pain management. Ended
  2024-519625-38-00 Phase III Postoperative pain relief 5med GmbH; CCDRD Cooperative Clinical Drug Research and Development AG
• A Research Study to See How Switching from a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar … Ended
  2023-506084-34-00 Phase III Type 2 Diabetes Novo Nordisk A/S
• A Safety, Tolerability and Efficacy Study of VRDN-001 in Persons with Chronic Thyroid Eye Disease (TED) Ended
  2023-507217-10-00 Phase III Thyroid eye disease Viridian Therapeutics Inc.
• A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Ended
  2023-503693-20-01 Phase III Severe eosinophilic asthma Areteia Therapeutics Inc.
• A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinet… Ended
  2023-505414-15-00 Phase II Dermatitis, Atopic Glaxosmithkline Research & Development Limited
• A placebo-controlled safety and tolerability study of intravenous (IV) and subcutaneous (SC) AZD1163 in healthy volunteers Ended
  2023-509574-34-00 Phase I Rheumatoid Arthritis AstraZeneca AB
• A study to assess the efficacy and safety of tigulixostat at different doses as compared to a control drug (allopurinol) in gout patients wi… Ended
  2022-501421-20-00 Phase III Gout with hyperuricemia LG Chem Ltd.
• A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia Ended
  2023-506707-25-00 Phase III Choroidal neovascularization secondary to pathologic myopia F. Hoffmann-La Roche AG
• A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to… Ended
  2023-504564-42-00 Phase II Moderate to Severe Rheumatoid Arthritis Anaptysbio Inc.
• HIV: Budigalimab and/or ABBV-382 in People Living with HIV on Stable Antiretroviral Therapy Ended
  2023-505900-53-00 Phase II HIV infection AbbVie Deutschland GmbH & Co. KG
• A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis Ended
  2023-505841-22-00 Phase III Moderate to Severe Plaque Psoriasis Takeda Development Center Americas Inc.
• A trial to learn about a study drug (STAR-0215) in adults with hereditary angioedema Ended
  2022-502953-32-01 Phase I/II Hereditary Angioedema (HAE) Astria Therapeutics Inc.
• Regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC beyond up-to-7. Ended
  2022-501969-42-00 Phase III Intermediate-stage hepatocellular carcinoma with beyond up-t… Translational Research In Oncology
• A Study to Evaluate the Efficacy and Safety of LASN01 in Patients with Thyroid Eye Disease Ended
  2023-508161-32-00 Phase II Thyroid Eye Disease Lassen Therapeutics 1 Inc.
• A Phase 2 Study of MK-4280A for the Treatment of Selected Solid Tumors Ended
  2023-505022-34-00 Phase II Neoplasm malignant Merck Sharp & Dohme LLC
• A research study Looking into blood levels of the medicine NNC0519-0130 in the body of participants with normal or reduced kidney function Ended
  2023-506381-32-00 Phase I Type 2 Diabetes Mellitus Novo Nordisk A/S
• Study to evaluate the safety and efficacy of Cipaglucosidase Alfa and Miglustat in pediatric subjects with late-onset Pompe disease Ended
  2022-502547-36-00 Phase III Late-onset Pompe disease Amicus Therapeutics Inc.

Showing 3,073–3,096 of 3,925 trials